Suppr超能文献

白细胞介素-1β可诱导p62/SQSTM1并抑制前列腺癌细胞中的雄激素受体表达。

IL-1β induces p62/SQSTM1 and represses androgen receptor expression in prostate cancer cells.

作者信息

Chang M A, Patel V, Gwede M, Morgado M, Tomasevich K, Fong E L, Farach-Carson M C, Delk Nikki A

机构信息

Department of BioSciences, Rice University, BioScience Research Collaborative, 6500 Main, MS 601, Houston, TX, 77030.

出版信息

J Cell Biochem. 2014 Dec;115(12):2188-97. doi: 10.1002/jcb.24897.

Abstract

Chronic inflammation is associated with advanced prostate cancer (PCa), although the mechanisms governing inflammation-mediated PCa progression are not fully understood. PCa progresses to an androgen independent phenotype that is incurable. We previously showed that androgen independent, androgen receptor negative (AR(-) ) PCa cell lines have high p62/SQSTM1 levels required for cell survival. We also showed that factors in the HS-5 bone marrow stromal cell (BMSC) conditioned medium can upregulate p62 in AR(+) PCa cell lines, leading us to investigate AR expression under those growth conditions. In this paper, mRNA, protein, and subcellular analyses reveal that HS-5 BMSC conditioned medium represses AR mRNA, protein, and nuclear accumulation in the C4-2 PCa cell line. Using published gene expression data, we identify the inflammatory cytokine, IL-1β, as a candidate BMSC paracrine factor to regulate AR expression and find that IL-1β is sufficient to both repress AR and upregulate p62 in multiple PCa cell lines. Immunostaining demonstrates that, while the C4-2 population shows a primarily homogeneous response to factors in HS-5 BMSC conditioned medium, IL-1β elicits a strikingly heterogeneous response; suggesting that there are other regulatory factors in the conditioned medium. Finally, while we observe concomitant AR loss and p62 upregulation in IL-1β-treated C4-2 cells, silencing of AR or p62 suggests that IL-1β regulates their protein accumulation through independent pathways. Taken together, these in vitro results suggest that IL-1β can drive PCa progression in an inflammatory microenvironment through AR repression and p62 induction to promote the development and survival of androgen independent PCa.

摘要

慢性炎症与晚期前列腺癌(PCa)相关,尽管炎症介导的PCa进展机制尚未完全明确。PCa会发展为无法治愈的雄激素非依赖型表型。我们之前发现,雄激素非依赖、雄激素受体阴性(AR(-))的PCa细胞系具有细胞存活所需的高p62/SQSTM1水平。我们还发现,HS-5骨髓基质细胞(BMSC)条件培养基中的因子可上调AR(+) PCa细胞系中的p62,这促使我们研究在这些生长条件下的AR表达。本文通过mRNA、蛋白质和亚细胞分析表明,HS-5 BMSC条件培养基可抑制C4-2 PCa细胞系中的AR mRNA、蛋白质及核内积累。利用已发表的基因表达数据,我们确定炎性细胞因子IL-1β是调节AR表达的候选BMSC旁分泌因子,并发现IL-1β足以在多个PCa细胞系中抑制AR并上调p62。免疫染色显示,虽然C4-2群体对HS-5 BMSC条件培养基中的因子表现出基本一致的反应,但IL-1β引发了显著的异质性反应;这表明条件培养基中存在其他调节因子。最后,虽然我们在IL-1β处理的C4-2细胞中观察到AR缺失和p62上调同时出现,但AR或p62的沉默表明IL-1β通过独立途径调节它们的蛋白质积累。综上所述,这些体外研究结果表明,IL-1β可通过抑制AR和诱导p62在炎症微环境中驱动PCa进展,以促进雄激素非依赖型PCa的发展和存活。

相似文献

1
IL-1β induces p62/SQSTM1 and represses androgen receptor expression in prostate cancer cells.
J Cell Biochem. 2014 Dec;115(12):2188-97. doi: 10.1002/jcb.24897.
2
p62/SQSTM1 is required for cell survival of apoptosis-resistant bone metastatic prostate cancer cell lines.
Prostate. 2014 Feb;74(2):149-63. doi: 10.1002/pros.22737. Epub 2013 Sep 30.
6
Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence.
PLoS One. 2020 Dec 16;15(12):e0242970. doi: 10.1371/journal.pone.0242970. eCollection 2020.
8
Cooperation among heterogeneous prostate cancer cells in the bone metastatic niche.
Oncogene. 2017 May 18;36(20):2846-2856. doi: 10.1038/onc.2016.436. Epub 2016 Dec 19.
9
Sin1 promotes proliferation and invasion of prostate cancer cells by modulating mTORC2-AKT and AR signaling cascades.
Life Sci. 2020 May 1;248:117449. doi: 10.1016/j.lfs.2020.117449. Epub 2020 Feb 21.

引用本文的文献

5
Exploring the role of the inflammasomes on prostate cancer: Interplay with obesity.
Rev Endocr Metab Disord. 2023 Dec;24(6):1165-1187. doi: 10.1007/s11154-023-09838-w. Epub 2023 Oct 11.
7
Role of Interleukin-1 family in bone metastasis of prostate cancer.
Front Oncol. 2022 Sep 27;12:951167. doi: 10.3389/fonc.2022.951167. eCollection 2022.
10
The Role of Androgen Receptor in Cross Talk Between Stromal Cells and Prostate Cancer Epithelial Cells.
Front Cell Dev Biol. 2021 Oct 6;9:729498. doi: 10.3389/fcell.2021.729498. eCollection 2021.

本文引用的文献

1
Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223.
Ther Clin Risk Manag. 2014 May 23;10:373-80. doi: 10.2147/TCRM.S45667. eCollection 2014.
2
Nrf2 and NF-κB and Their Concerted Modulation in Cancer Pathogenesis and Progression.
Cancers (Basel). 2010 Apr 13;2(2):483-97. doi: 10.3390/cancers2020483.
3
Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer.
BJU Int. 2014 Aug;114(2):168-76. doi: 10.1111/bju.12488. Epub 2014 Feb 20.
4
p62/SQSTM1 is required for cell survival of apoptosis-resistant bone metastatic prostate cancer cell lines.
Prostate. 2014 Feb;74(2):149-63. doi: 10.1002/pros.22737. Epub 2013 Sep 30.
5
Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features.
Cancer Res. 2013 Jun 1;73(11):3297-305. doi: 10.1158/0008-5472.CAN-12-3970. Epub 2013 Mar 27.
6
The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism.
Front Oncol. 2012 Dec 26;2:200. doi: 10.3389/fonc.2012.00200. eCollection 2012.
7
Chronic inflammation in cancer development.
Front Immunol. 2012 Jan 12;2:98. doi: 10.3389/fimmu.2011.00098. eCollection 2011.
9
p62: a versatile multitasker takes on cancer.
Trends Biochem Sci. 2012 Jun;37(6):230-6. doi: 10.1016/j.tibs.2012.02.008. Epub 2012 Mar 15.
10
Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.
Oncologist. 2012;17(2):212-9. doi: 10.1634/theoncologist.2011-0321. Epub 2012 Feb 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验